Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Apitope logo — Develops drugs for treatments of allergic diseases

Apitope

Develops drugs for treatments of allergic diseases

Founded 2002 Belgium Belgium 1 employees Series B Total: $22.00M Biotechnology, Health Care

General Information

Company Name Apitope
Founded Year 2002
Location Belgium Belgium
Founders / Decision Makers
Team member
Employees 1
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Apitope. To contact Apitope, visit apitope.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Apitope compare?

A PDF of Apitope and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Apitope soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Apitope

Apitope, a Belgium-based biotech company founded in 2002, is focused on developing drugs for the treatment of allergic diseases. The company positions itself at the forefront of antigen-specific immunotherapy, employing a proprietary discovery platform for creating peptide-based therapies known as "apitopes®." These therapies aim to restore immune tolerance, providing a targeted approach to autoimmune diseases without the drawbacks of global immune suppression.

The company's leading product candidate, ATX-MS-1467, is in clinical development for multiple sclerosis (MS), offering a promising combination of high efficacy and a differentiating safety profile. Additionally, ATX-GD-59 targets Graves' disease, potentially revolutionizing treatment standards for the first time in over 60 years.

Noteworthy in Apitope's evolution is a €12.00M Series B investment received in September 2015 from investors including Vesalius Biocapital, Arthurian Life Sciences, Wyvern Seed Fund, and PMV Pharmaceuticals.

Business keywords: biotech, clinical-stage, autoimmune diseases, antigen-specific immunotherapeutics, peptide-based therapies, immune tolerance, multiple sclerosis, Graves' disease, robotpipeline, innovative treatments, drug development, immunological treatments, pharmaceutical industry, merck serono partnership

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €12.00M 4
Vesalius Biocapital Arthurian Life Sciences
Vesalius Biocapital, Arthurian Life Sciences +2
01 Sep 2015
Grant Undisclosed -
01 Dec 2012
Series A €10.00M 2
Vesalius Biocapital Vinno Capital
Vesalius Biocapital, Vinno Capital
01 Oct 2008
Spinout Undisclosed 1
Hasselt University
01 Jan 2008

Apitope Alternatives & Competitors

View All Alternatives
Apitope vs
Cyxone
Cyxone Sweden

Life-changing treatments for disorders of the immune system

11 employees
Biotechnology, Health Care
Apitope vs
Bionure
Bionure Spain

Clinical stage biotech developing new drugs for CNS diseases.

Series A
8 employees
Biotechnology, Health Care
Apitope vs
AnTolRx
AnTolRx

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary na...

Series A
Biotechnology, Health Care
View all alternatives

FAQ About Apitope

Develops drugs for treatments of allergic diseases
Apitope was founded in 2002.
Apitope is headquartered in Belgium.
Apitope operates in Biotechnology and Health Care. Its work centres on biotech, clinical-stage, autoimmune diseases and antigen-specific immunotherapeutics.
Apitope has approximately 1 employees.
Apitope has completed 4 funding rounds, raising a total of $22.00M. The latest funding stage is Series B.
Top alternatives and competitors to Apitope include Cyxone, Bionure, AnTolRx, Vigil Neuroscience, Cinclus Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Apitope and Cyxone are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Apitope, https://bouncewatch.com/company/apitope, updated 12 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout